Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
Am J Clin Dermatol ; 12(3): 210-3, 2011 Jun 01.
Article in English | MEDLINE | ID: mdl-21469764

ABSTRACT

The term 'baboon syndrome' was introduced in 1984 to describe a special form of systemic, contact-type dermatitis that occurs after ingestion or systemic absorption of a contact allergen in individuals previously sensitized by topical exposure to the same allergen in the same areas. Its clinical picture presents as an erythema of the buttocks and upper inner thighs resembling the red bottom of baboons. This reaction was originally observed with mercury, nickel, and ampicillin. In 2004, some authors proposed the acronym SDRIFE standing for 'symmetric drug-related intertriginous and flexural exanthema' specifically for cases elicited by systemically administered drugs. Since 1984, about 100 cases have been reported in the literature; for most of the concerned drugs, previous skin sensitization or possible cross-sensitization has not been shown. We report the first case of SDRIFE due to rivastigmine, with the exception of an erythematous maculopapular eruption due to rivastigmine that was previously reported. Rivastigmine is a reversible and noncompetitive acetylcholinesterase inhibitor used for the treatment of Alzheimer disease. SDRIFE is an important condition to keep in mind in order to avoid a misdiagnosis when dealing with other exanthematous disorders and to prevent re-exposure to the responsible allergen in the future.


Subject(s)
Drug Eruptions/etiology , Exanthema/chemically induced , Phenylcarbamates/adverse effects , Aged, 80 and over , Buttocks , Cholinesterase Inhibitors/adverse effects , Cholinesterase Inhibitors/therapeutic use , Dementia/drug therapy , Dermatitis, Allergic Contact/diagnosis , Dermatitis, Allergic Contact/etiology , Drug Eruptions/diagnosis , Exanthema/diagnosis , Humans , Intertrigo/chemically induced , Intertrigo/diagnosis , Male , Phenylcarbamates/therapeutic use , Rivastigmine , Syndrome
2.
Eur J Clin Pharmacol ; 64(4): 433-7, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18185925

ABSTRACT

BACKGROUND: Because the elderly are often treated by multiple-drug regimens, their iatrogenic risks are considerably raised. However, despite the serious side-effects that diuretic agents may have in this population, SPCs (summary of product characteristics) do not specify how often serum chemistry should be monitored. This study of long-term diuretic therapy prescription and monitoring in elderly patients was conducted by the Department of Clinical Pharmacology of the Nantes teaching hospital in collaboration with the medical department of the French national health insurance scheme. METHODS: Data were extracted from the French national health insurance database. Patients were 75 years old or more and had been receiving a diuretic agent for 1 year or longer. The patients were classified into two groups: one group included those patients whose serum chemistry had been monitored at least once (electrolyte levels and/or urea and creatinine blood levels); the other group included the non-monitored patients. RESULTS: Mean patient age was 80+/-4.6 (SD) years. The non-monitored patients represented 22.8% of the cohort. The at-risk patients were mainly women suffering from no severe disease, treated by a single practitioner (often a general practitioner) and/or always receiving the same type of diuretic agent. CONCLUSION: Many elderly patients receiving diuretic agents do not benefit from regular serum chemistry monitoring. The prescription of serum chemistry assays is correlated to the presence of various patient-related risk factors. Recommendations should be made to help practitioners to ensure a minimal serum chemistry monitoring in all elderly patients receiving diuretics.


Subject(s)
Aged/physiology , Diuretics/therapeutic use , Aged, 80 and over , Cohort Studies , Databases, Factual , Diuretics/administration & dosage , Drug Interactions , Drug Monitoring , Drug Prescriptions , Drug Therapy, Combination , Female , France/epidemiology , Humans , Logistic Models , Long-Term Care , Male , National Health Programs
3.
Pharmacol Res ; 56(1): 11-7, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17572097

ABSTRACT

PURPOSE: The objective of the current study was to determine the ability of some antiemetic compounds to cross the blood-brain barrier (BBB) and thereby to determine possible side effects of compounds for the central nervous system (CNS). METHODS: We compared the brain penetration of some antiemetic compounds using an in vitro BBB model consisting in brain capillary endothelial cells co-cultured with primary rat glial cells. RESULTS: This study clearly demonstrated that the metopimazine metabolite, metopimazine acid, has a very low brain penetration, lower than metopimazine and even less than the other antiemetic compounds tested in this study. CONCLUSIONS: The poor brain penetration of metopimazine acid, metopimazine biodisponible form, seems very likely related to the clinically observed difference in therapeutic and safety profile.


Subject(s)
Antiemetics/pharmacokinetics , Blood-Brain Barrier/metabolism , Chlorpromazine/pharmacokinetics , Domperidone/pharmacokinetics , Isonipecotic Acids/pharmacokinetics , Metoclopramide/pharmacokinetics , Animals , Animals, Newborn , Antiemetics/metabolism , Brain/cytology , Brain/metabolism , Capillary Permeability , Cells, Cultured , Chlorpromazine/metabolism , Claudin-1 , Coculture Techniques/methods , Domperidone/metabolism , Endothelial Cells/cytology , Endothelial Cells/metabolism , Endothelium, Vascular/metabolism , Isonipecotic Acids/metabolism , Membrane Proteins/analysis , Metoclopramide/metabolism , Neuroglia/cytology , Neuroglia/metabolism , Occludin , Phosphoproteins/analysis , Rats , Sucrose/metabolism , Tight Junctions/chemistry , Tight Junctions/metabolism , Zonula Occludens-1 Protein
SELECTION OF CITATIONS
SEARCH DETAIL
...